Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Jens Bedke,Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Tom Waddell, Dimitry Nosov,Frederic Pouliot,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Sergio J. Azevedo,Delphine Borchiellini,Raymond S. McDermott,Satoshi Tamada,Allison Martin Nguyen,Shuyan Wan,Rodolfo F. Perini,L. Rhoda Molife,Michael B. Atkins

European Urology（2022）

引用 15|浏览20

暂无评分

摘要

First-line pembrolizumab + axitinib significantly improved overall survival, progression-free survival, and objective response rate over sunitinib, while health-related quality of life outcomes were not different between groups.

查看译文

关键词

Advanced renal cell carcinoma,Axitinib,Health-related quality of life,Pembrolizumab,Sunitinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要